Broadening the Efficacy of Cancer Immunotherapies

在过去的5年中，针对免疫调节受体的抗体，如Ipilimumab， Nivolumab/Pembrolizumab，在导致晚期癌症的长期肿瘤消退和无病生存方面具有革命性意义。我的愿景是通过探索新的途径和组合，优化它们的时间表，并在小鼠模型中评估它们的安全性，从而增加对免疫治疗有反应的癌症患者的比例，从而使它们能够快速转化为临床。

Over the past 5 years, antibodies targeting immunomodulatory receptors such as Ipilimumab, Nivolumab/Pembrolizumab have been revolutionary in causing long term tumor regression and disease free survival in advanced cancers. My vision is to increase the proportion of cancer patients that will respond to immunotherapy by exploring novel pathways and combinations and optimizing their scheduling and assessing their safety in mouse models to allow their rapid translation into the clinic.